Beth A. Zamboni

996 total citations
34 papers, 790 citations indexed

About

Beth A. Zamboni is a scholar working on Oncology, Biomaterials and Molecular Biology. According to data from OpenAlex, Beth A. Zamboni has authored 34 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Biomaterials and 13 papers in Molecular Biology. Recurrent topics in Beth A. Zamboni's work include Nanoparticle-Based Drug Delivery (15 papers), Cancer therapeutics and mechanisms (10 papers) and Lung Cancer Research Studies (9 papers). Beth A. Zamboni is often cited by papers focused on Nanoparticle-Based Drug Delivery (15 papers), Cancer therapeutics and mechanisms (10 papers) and Lung Cancer Research Studies (9 papers). Beth A. Zamboni collaborates with scholars based in United States, South Korea and Israel. Beth A. Zamboni's co-authors include William C. Zamboni, Sandra Strychor, Paola A. Gehrig, Ninh M. La‐Beck, Ramesh K. Ramanathan, William E. Gooding, Jennifer R. Grandis, Suresh S. Ramalingam, Alberto Gabizón and Michael Amantea and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Beth A. Zamboni

34 papers receiving 778 citations

Peers

Countries citing papers authored by Beth A. Zamboni

Since Specialization

Citations

This map shows the geographic impact of Beth A. Zamboni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth A. Zamboni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth A. Zamboni more than expected).

Fields of papers citing papers by Beth A. Zamboni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth A. Zamboni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth A. Zamboni. The network helps show where Beth A. Zamboni may publish in the future.

Co-authorship network of co-authors of Beth A. Zamboni

This figure shows the co-authorship network connecting the top 25 collaborators of Beth A. Zamboni. A scholar is included among the top collaborators of Beth A. Zamboni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth A. Zamboni. Beth A. Zamboni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer 2025 ·Clinical and Translational Science ·Li Chen, Andrew T. Lucas, Aaron S. Mansfield, Stéphanie Lheureux, C.J. O’Connor, Beth A. Zamboni, (unknown), Tawnya C. McKee, Jeffrey A. Moscow, William C. Zamboni	3
2	Satisfaction and Technology Acceptance of Staff Regarding Use of Continuous Video Monitoring in Comparison With Sitters 2021 ·JONA The Journal of Nursing Administration ·(unknown), (unknown), Elisabeth George, Beth A. Zamboni	14
3	Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer 2016 ·Cancer Chemotherapy and Pharmacology ·Hugh Giovinazzo, Parag Kumar, Arif Sheikh, Kristina M. Brooks, Marija Ivanović, Mark D. Walsh, (unknown), Richard J. Kowalsky, Gina Song, (unknown), Daniel L. Clarke‐Pearson, Wendy R. Brewster, Linda Van Le, Beth A. Zamboni, Victoria Bae‐Jump, Paola A. Gehrig, William C. Zamboni	19
4	Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors 2015 ·International Journal of Nanomedicine ·Huali Wu, Jeffrey R. Infante, Vicki L. Keedy, Suzanne F. Jones, Emily Chan, Johanna C. Bendell, Wooin Lee, (unknown), Beth A. Zamboni, Satoshi Ikeda, Hiroshi Kodaira, Mace L. Rothenberg, (unknown), William C. Zamboni	14
5	Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents 2013 ·Nanomedicine Nanotechnology Biology and Medicine ·(unknown), (unknown), (unknown), Mark D. Walsh, (unknown), Beth A. Zamboni, Ramesh K. Ramanathan, William C. Zamboni	38
6	A Review of Study Designs and Outcomes of Phase I Clinical Studies of Nanoparticle Agents Compared with Small-Molecule Anticancer Agents 2013 ·Clinical Cancer Research ·(unknown), (unknown), Beth A. Zamboni, William C. Zamboni	26
7	Population Pharmacokinetics of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies 2011 ·The Journal of Clinical Pharmacology ·Huali Wu, Ramesh K. Ramanathan, Beth A. Zamboni, Sandra Strychor, Suresh S. Ramalingam, Robert P. Edwards, David Friedland, Ronald G. Stoller, Chandra P. Belani, (unknown), Yung‐Jue Bang, William C. Zamboni	30
8	Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients 2011 ·Cancer Chemotherapy and Pharmacology ·Ninh M. La‐Beck, Beth A. Zamboni, Alberto Gabizón, (unknown), Michael Amantea, Paola A. Gehrig, William C. Zamboni	96
9	Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer 2011 ·Cancer Chemotherapy and Pharmacology ·William C. Zamboni, Austin J. Combest, Julie A. DeLoia, Robert P. Edwards, Arlene S. Bridges, Beth A. Zamboni, Christine M. Walko, Angela Yu, Thomas C. Krivak, Joseph L. Kelley	12
10	Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models 2010 ·Journal of Liposome Research ·William C. Zamboni, Julie L. Eiseman, Sandra Strychor, (unknown), Erin Joseph, Beth A. Zamboni, (unknown), (unknown), Robert A. Parise, Margaret Tonda, Ning Yu, Per Basse	23
11	Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors 2010 ·Journal of Liposome Research ·William C. Zamboni, (unknown), Sandra Strychor, Beth A. Zamboni, Suresh S. Ramalingam, Robert P. Edwards, (unknown), (unknown), (unknown), David Friedland, Ronald G. Stoller, Chandra P. Belani, Ramesh K. Ramanathan	38
12	Abstract 3700: Effect of gender on pharmacokinetic disposition of pegylated liposomal CKD-602 (S-CKD602) and optisomal topotecan (TLI) in rats 2010 ·Cancer Research ·Gina Song, Huali Wu, Ninh M. La‐Beck, Beth A. Zamboni, (unknown), (unknown), (unknown), William C. Zamboni	5
13	Pharmacokinetics (PK) of oxaliplatin (OX) after intraperitoneal (IP) and intravenous (IV) administration in patients with gynecological malignancies. 2010 ·Journal of Clinical Oncology ·Austin J. Combest, Kristin K. Zorn, Robert P. Edwards, Suzan K. Hanna, (unknown), (unknown), Beth A. Zamboni, Thomas C. Krivak, (unknown), (unknown)	1
14	Abstract C127: Factors affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors 2009 ·Molecular Cancer Therapeutics ·Huali Wu, Jeffrey R. Infante, Suzanne F. Jones, Howard A. Burris, Emily Chan, Vicki L. Keedy, Johanna C. Bendell, Beth A. Zamboni, Hiroshi Kodaira, Satoshi Ikeda, William C. Zamboni	3
15	Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice 2008 ·Investigational New Drugs ·William C. Zamboni, Laura Jung, Sandra Strychor, Erin Joseph, Beth A. Zamboni, (unknown), (unknown), Thomas G. Burke, Dennis P. Curran, Julie L. Eiseman	6
16	Evaluation of body surface area (BSA) based dosing, age, and body composition as factors affecting the pharmacokinetic (PK) variability of STEALTH liposomal doxorubicin (Doxil) 2007 ·Molecular Cancer Therapeutics ·(unknown), Robert P. Edwards, Beth A. Zamboni, Sandra Strychor, (unknown), William C. Zamboni	8
17	Age-related effects on the pharmacodynamic (PD) relationship between STEALTH liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors 2007 ·Journal of Clinical Oncology ·(unknown), Rajesh Ramanathan, (unknown), Beth A. Zamboni, Suresh S. Ramalingam, (unknown), (unknown), Yung‐Jue Bang, (unknown), William C. Zamboni	5
18	Decreased STAT1 Expression by Promoter Methylation in Squamous Cell Carcinogenesis 2006 ·JNCI Journal of the National Cancer Institute ·Sichuan Xi, Kevin F. Dyer, Mark A. Kimak, Qing Zhang, William E. Gooding, J. Richard Chaillet, Raymond L. Chai, Robert E. Ferrell, Beth A. Zamboni, Jennifer L. Hunt, Jennifer R. Grandis	72
19	Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer 2004 ·Annals of Oncology ·Suresh S. Ramalingam, Chandra P. Belani, Roger Day, Beth A. Zamboni, Samuel A. Jacobs, James R. Jett	14
20	The Gender Gap in a Surgical Subspecialty 2004 ·Archives of Otolaryngology - Head and Neck Surgery ·Jennifer R. Grandis, William E. Gooding, Beth A. Zamboni, Marilyn M. Wagener, Stephanie D. Drenning, (unknown), Karen Jo Doyle, Susan E. Mackinnon, Robin L. Wagner	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact